• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Aclarion Inc.

    3/31/25 4:30:26 PM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    NT 10-K 1 aclarion_ext.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON D.C. 20549

     

    FORM 12b-25

    NOTIFICATION OF LATE FILING

     

     

    (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K        
      ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR    

     

    For Period Ended: December 31, 2024

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended: _______________________________________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

    PART I - REGISTRANT INFORMATION

     

    Aclarion, Inc.


    Full Name of Registrant

     

     


    Former Name if Applicable

     

    8181 Arista Place, Suite 100


    Address of Principal Executive Office (Street and Number)

     

    Broomfield, CO 80021


    City, State, Zip Code

     

     

     

       

     

     

    PART II - RULES 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject ☐ quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    Aclarion, Inc. (the “Company”) is unable to file its annual report on Form 10-K for the year ended December 31, 2024 within the prescribed time period without unreasonable effort and expense. We are requesting more time to compile the necessary information for the preparation of the 10-K report, and to allow more time for our independent registered public accounting firm to review our financial statements.

     

    The Company believes it will be able to file the annual report on or before the fifteenth calendar day following the prescribed due date.

     

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification:

     

    John Lorbiecki

     

    833

      275-2266
    (Name)   (Area Code)   (Telephone No.)

     

    (2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
      ☒ Yes ☐ No
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      ☐ Yes ☒ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    _______________________________________________________________________________________

     

     2 

     

     

    Aclarion, Inc.


    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

    Date: March 31, 2025 By:

    /s/ John Lorbiecki

      Name: John Lorbiecki
      Title: Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     3 

     

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclarion Publishes 2026 Shareholder Letter from the Chairman

    Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman. The letter outlines significant clinical, financial, and operational priorities as the company advances toward an expected initia

    2/5/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

    Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan's non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedureSupports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established an agreement with Source Heal

    2/3/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

    BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise structure. The transaction materially strengthens Aclarion's balance sheet, preserves capital structure integrity, and significantly extends the Company's operating runway well past targeted near and medium-term catalysts while enhancing strategic flexibi

    1/13/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 4 filed by CFO Gould Gregory A

    4 - Aclarion, Inc. (0001635077) (Issuer)

    9/3/25 5:10:03 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Gould Gregory A

    3 - Aclarion, Inc. (0001635077) (Issuer)

    9/3/25 5:05:26 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    SEC Filings

    View All

    Aclarion Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aclarion, Inc. (0001635077) (Filer)

    1/13/26 9:00:25 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Aclarion, Inc. (0001635077) (Filer)

    1/9/26 9:03:07 AM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Aclarion Inc.

    424B5 - Aclarion, Inc. (0001635077) (Filer)

    1/9/26 9:00:15 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

    Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers covering NociscanNociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announc

    11/5/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Greg Gould as Chief Financial Officer

    HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity BROOMFIELD, Colo., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced the appointment of Greg Gould as Chief Financial Officer (CFO), effective immediately. Greg brings mor

    9/3/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    11/13/24 3:06:29 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Aclarion Inc.

    SC 13G - Aclarion, Inc. (0001635077) (Subject)

    9/5/24 4:19:39 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    3/29/24 5:00:57 PM ET
    $ACON
    Medical Specialities
    Health Care